Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for investment professionals · Thursday, December 13, 2018 · 471,017,450 Articles · 3+ Million Readers

CV Sciences, Inc. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Nevada against CV Sciences, Inc.   

Lead Plaintiff Deadline is October 23, 2018     

NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action lawsuit has been filed in the United States District for the District of Nevada against CV Sciences, Inc. ("CV Sciences" or the "Company") (OTCMKT: CVSI) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired CV Sciences securities between June 19, 2017 and August 20, 2018, both dates inclusive (the “Class Period”). 

Investors who have incurred losses in the shares of CV Sciences, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If   you  have  incurred  losses  in  the shares of CV Sciences, Inc., you may, no later than October 23, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in CV Sciences, Inc.  

The filed Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that its Patent #15/426,617:

  • received a non-final rejection from the USPTO on April 27, 2017;
     
  • a final rejection from the USPTO on December 14, 2017; and
     
  • consequently, Defendants' statements about CV Sciences' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. 

On August 20, 2018, Citron Research alleged that CV Sciences misrepresented the status of one of its key patents. Citron Research said that the Company failed to disclose a rejected patent that the Company "continued to hype."

Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

Follow the firm and learn about newly filed cases on Twitter and Facebook.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

/EIN News/ --

wolf_logo_color_tagline.jpg

Powered by EIN News
Distribution channels: Consumer Goods, Law


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release